Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.
about
Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infectionsComputerized advice on drug dosage to improve prescribing practiceBench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit.Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatricsLimited predictability of amikacin clearance in extreme premature neonates at birthThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemPharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infectionComparison of 2 techniques for regional antibiotic delivery to the equine forelimb: intraosseous perfusion vs. intravenous perfusionValidation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapyVentilator-associated pneumonia: diagnosis, treatment, and preventionPharmacokinetic Changes and Dosing Modification of Aminoglycosides in Critically Ill Obese Patients: A Literature ReviewAntimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.Population pharmacokinetics of netilmicin in short-term prophylactic treatmentAudiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-upOptimal aminoglycoside dosing regimen for penicillin-tobramycin synergism in experimental Streptococcus adjacens endocarditis.A Bayesian Modelling Approach with Balancing Informative Prior for Analysing Imbalanced Data.Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) studyAminoglycosides: activity and resistance.Aminoglycosides: nephrotoxicityOnce-daily aminoglycosides in the treatment of gram-positive endocarditis.Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adultsIn vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa.Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms.Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-LactamsFever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokineticsExploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infectionsPharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyRevisiting the loading dose of amikacin for patients with severe sepsis and septic shockAmbulatory use of parenteral antibacterials: contemporary perspectives.Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteriaCharacterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.Bactericidal activity of gentamicin against Enterococcus faecalis in vitro and in vivo.Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis modelNew developments and concepts in antimicrobial therapy for intra-abdominal infections.Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection modelIndividualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.
P2860
Q24199096-20E9EE52-94B6-4C50-A8C7-F21B7F7C22C1Q24202497-723A5BBF-5C1D-4348-9AC7-C3461F011C11Q24813204-4E52244C-136A-4A88-BCB4-658A7BD9E8F6Q26853629-6FCF4C51-EEC3-441A-83DF-B794F94B2F65Q28194278-A4E9ED03-5043-4819-98BB-103A6A5B34A2Q28289744-F441698B-F2BD-4EFF-93DA-8D9B6947FD32Q28328534-9F8EA0F3-1EF2-4107-84FE-E796A0BF033AQ28346609-C5798245-F59B-423F-9904-F9C9B8928891Q28379292-638BDA84-443F-46E5-B805-E79D95F56108Q29012676-FF38937D-ECBE-4734-A381-A8DC524CD614Q29248398-4E6900DD-B303-4B7E-8421-E4A191E3AD09Q30326190-546655A8-8935-4A3B-ACFF-5540CCB30E18Q30498412-C256DC24-471A-4A88-9AD6-46CDD23FAD26Q30838132-22C3CCA1-96FD-4D9A-817D-A2028FDE733DQ30901078-3A58BDD8-783F-42A1-B748-5B633E89EF5DQ31075196-558981C7-3E42-4112-A1A5-74F8C6A30C39Q33518061-677B5471-65BD-4D62-B3DA-319A930F4849Q33548221-0B97C83F-0623-4264-A98F-C8E9C78919F5Q33605648-01A651B0-3D8B-4E59-8A8C-FE9C017A7BA7Q33659372-AA8BDF6A-7E7E-4856-AD75-3C540870832AQ33692660-E56647AC-BA4D-4ED9-A516-BD4458FDE170Q33694035-68CF017C-D3D3-4574-9316-4FD6CC5DD77FQ33694513-60B30472-357E-46B1-A238-C780FB340DDBQ33695281-34C6430A-9681-4660-9B74-72679684C838Q33696025-EF6D82B3-718B-4359-9AE8-0DB76B3B07ACQ33751758-A1B9E9DE-3354-47CC-BED8-2686DD3AE0B8Q33767602-0CE05426-791A-4B76-AFDF-3E0ACC3511FEQ33827819-1BBBA5EE-2A0D-4C10-9E07-786DC8E70EB6Q33919190-AB295565-BF2A-43D9-B087-E7CC55317267Q33938974-ADA253CE-5C2E-49B4-A714-9EFDD3103518Q33976467-7C200467-58D7-43BF-AD28-8169C0DD30A9Q33977551-14008A22-E6AE-4DF2-A7A0-A3FCF8AF5E6CQ33979115-DA4BE280-0003-4F3C-8625-E31DD39DEAB3Q33980188-D28BC4DF-E5CD-4D57-8AF1-9C1E2CF84485Q33981666-41362308-1642-4250-AED7-CA1BD4968CD9Q33981712-71AD4F89-97C9-415E-8AAF-FE2CD3A6FC91Q34028070-9CB52F0D-A734-4EFE-AD23-89F9BE90BD87Q34106577-4716F667-F6A9-44D9-927A-4CE5C69A1DF5Q34106959-48039EB5-DE51-43AB-9B61-A34EFD028D05Q34274190-1DC78BBA-4D88-4B45-A225-04632DEAA39A
P2860
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Clinical response to aminoglyc ...... imal inhibitory concentration.
@en
Clinical response to aminoglyc ...... imal inhibitory concentration.
@nl
type
label
Clinical response to aminoglyc ...... imal inhibitory concentration.
@en
Clinical response to aminoglyc ...... imal inhibitory concentration.
@nl
prefLabel
Clinical response to aminoglyc ...... imal inhibitory concentration.
@en
Clinical response to aminoglyc ...... imal inhibitory concentration.
@nl
P2093
P356
P1476
Clinical response to aminoglyc ...... imal inhibitory concentration.
@en
P2093
P356
10.1093/INFDIS/155.1.93
P407
P577
1987-01-01T00:00:00Z